You are not really sleeping. You are unconscious for seven hours, but you wake unrested, you remember nothing, and the deep stages where the body actually repairs itself never showed up on the chart. DSIP was discovered in 1977 because researchers wanted to know what molecule could induce that exact missing stage on demand. Here is what it does, what it does not, the dosing that actually works, and the side effects nobody warned you about.
🔑 Key Takeaways
- DSIP (Delta Sleep-Inducing Peptide, sometimes called emideltide) is a 9-amino-acid neuropeptide isolated from rabbit brain in 1977. It is one of the original "sleep peptides" and remains the most studied compound for delta-wave (deep slow-wave) sleep promotion.
- The mechanism is not classic sedation. DSIP shifts sleep architecture by promoting delta-wave activity through HPA axis modulation (lower cortisol), GABAergic signaling, and indirect serotonin and growth hormone effects. It does not knock you out the way benzodiazepines do.
- Standard community dosing is 100 to 300 mcg subcutaneous, 30 to 60 minutes before sleep, cycled 5 to 10 days on with 5 to 14 days off. Higher doses (over 300 to 500 mcg) commonly cause morning grogginess without better sleep.
- Side effects are mild and uncommon: vivid dreams (20 to 30% of users, often welcomed rather than feared), morning grogginess at higher doses, occasional mild dizziness or headache, transient injection-site reactions. No published lethal dose.
- The 1984 Schneider trial data is the most-overlooked clinical signal: 87% of opioid-dependent patients and 97% of alcohol-dependent patients in DSIP-treated cohorts showed improved sleep and reduced withdrawal severity. Modern RCT evidence is thinner.
- FDA placed DSIP on Category 2 ("do not compound") in September 2023, with potential reclassification under review as of February 2026. It is not a controlled substance and not a banned substance, but compounding pharmacies cannot prepare it.
- DSIP is not a melatonin replacement. Melatonin shifts circadian timing. DSIP shifts sleep architecture. They target different problems and can be used together if the protocol calls for it.
- For chronic insomnia not responding to behavioral and conventional approaches, DSIP is one of the lower-risk peptides to try. For circadian or shift-work issues, melatonin is the better fit. For anxiety-driven sleeplessness, Selank or oxytocin overlap.
This page covers everything DSIP actually does: the molecule, the mechanism, the dosing protocols that work and the ones that backfire, the side effects you should expect, the clinical history including the underused withdrawal data, and how DSIP compares to melatonin and to other sleep peptides.
What Is DSIP?
A 9-amino-acid sleep-architecture peptide.
DSIP (Delta Sleep-Inducing Peptide) is a small endogenous peptide first isolated from the cerebral venous blood of sleeping rabbits in 1977 by Monnier and Schoenenberger at the University of Bern. It was named for the EEG signature it produced: increased delta-wave activity, the brain rhythm of deep slow-wave sleep. The synthetic version is sometimes called emideltide. The amino acid sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, written in single-letter notation as WAGGDASGE.
DSIP at a Glance
- Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE), 9 amino acids
- Molecular weight: ~850 daltons
- Discovered: 1977 by Monnier and Schoenenberger (University of Bern)
- Synthetic name: Emideltide
- Plasma half-life: 7 to 15 minutes
- Effective duration: Multiple nights post-dose, suggesting downstream signaling
- Common doses: 100 to 300 mcg subcutaneous before bed
- FDA status: Category 2 ("do not compound") since September 2023; not approved for human use; not a controlled substance
What makes DSIP different from sedative drugs
Sedatives (benzodiazepines, Z-drugs like zolpidem, quetiapine off-label, antihistamines) work by suppressing the central nervous system through GABA potentiation or histamine blockade. They reduce sleep latency and produce unconsciousness, but they often degrade sleep architecture: less REM, less deep delta sleep, more fragmentation, daytime carryover. The "you slept eight hours and feel terrible" phenomenon is partly because the drug blocked the stages your brain needed.
DSIP works upstream of that. It does not push you into unconsciousness. It nudges sleep architecture toward more delta-wave (slow-wave) activity, which is the stage when the body actually repairs and the brain consolidates. Users describe it less as "knockout" and more as "deeper, more refreshing sleep that started normally". The effect is subtle on the first night and tends to compound over a 5 to 10 day cycle.
How DSIP Works
The mechanism is multi-pathway, which is partly why the effect compounds.
| Pathway | What DSIP does | Downstream effect |
|---|---|---|
| HPA axis modulation | Reduces hypothalamic CRF and pituitary ACTH | Lower cortisol at night, less stress-driven awakenings |
| GABAergic signaling | Indirect potentiation of GABA-A activity | Reduced cortical arousal, easier sleep onset |
| Delta-wave promotion | Increases EEG delta activity | Deeper slow-wave sleep stages 3 to 4 |
| Growth hormone modulation | Indirect GHRH stimulation | GH pulses during sleep, supporting recovery |
| Serotonin pathway | Modulates 5-HT signaling | Mood stability, normalized sleep architecture |
| Opioid receptor modulation | Indirect met-enkephalin and endorphin release | Pain reduction, withdrawal symptom relief |
| NMDA glutamate | Mild interaction with NMDA receptors | Anti-excitotoxic, neuroprotective |
| Mitochondrial function | Supports ATP availability in neurons | Cellular energy maintenance during stress |
The reason a 7 to 15 minute plasma half-life produces multi-night effects is that DSIP appears to trigger downstream gene expression and second-messenger cascades that persist long after the peptide itself is cleared. This is why users typically describe the third or fourth night of a cycle as the best, not the first.
DSIP Benefits
What the data and user experience converge on.
Improved sleep quality and depth
The headline use case. Polysomnography studies from the 1980s and 1990s consistently show DSIP increases delta-wave activity and total sleep time, with most subjects reporting subjectively deeper, more refreshing sleep. Users with chronic insomnia (the population most likely to try it) report falling asleep faster, fewer nighttime awakenings, and better morning recovery, usually noticeable within 3 to 5 nights of starting.
Cortisol and stress reduction
HPA axis modulation lowers nighttime cortisol, which is one of the most common drivers of 3 AM awakenings. Users with stress-driven sleep disruption (the 3 to 4 AM "wired but tired" awakening) often report this is the symptom that improves first.
Withdrawal support (the underused signal)
The 1984 Schneider trial, published in major Russian and German addiction-medicine journals, showed:
- 97% of alcohol-dependent patients on DSIP showed improved sleep and reduced withdrawal severity
- 87% of opioid-dependent patients on DSIP showed comparable improvements
- 6 of 7 chronic pain patients reported pain relief
- 6 of 7 severe insomnia patients showed normalized sleep architecture over 3 to 7 months
This is the most overlooked DSIP application. The mechanism (opioid receptor modulation plus HPA axis softening plus deep sleep restoration) lines up with what people in withdrawal need. Modern RCT confirmation is thin, but the original 1984 cohort data is striking.
Growth hormone support
Through indirect GHRH stimulation, DSIP supports the natural GH pulses that occur during slow-wave sleep. The effect is smaller than dedicated GH peptides like CJC-1295 + ipamorelin, but it pairs well with them. For users running a GH stack, DSIP can be the sleep optimizer that lets the GH peptides work as intended.
Vivid dreams (a feature, not a bug)
20 to 30% of DSIP users report noticeably more vivid dreams during use. This is not a side effect in the negative sense; it is a marker of healthy REM activity coming back online. Users who had been sleep-deprived or on sedatives often describe the vivid dreams as the first sign their sleep is normalizing.
What DSIP does not do
- It does not put you to sleep on demand. If you take DSIP at 11 PM and your circadian rhythm says you are not tired until 2 AM, DSIP will not bridge that gap.
- It does not fix shift work or jet lag. Those are circadian problems. Use melatonin or light therapy.
- It does not produce immediate euphoria or sedation. The effect is subtle and architectural.
- It does not replace addressing the cause. Sleep apnea, untreated anxiety, alcohol, late caffeine, screens. Fix those first.
DSIP Dosage
Less is more, and timing matters.
| Phase | Daily dose | Timing | Cycle |
|---|---|---|---|
| Starter | 50 to 100 mcg | 30 to 60 min before bed | Try 5 nights, assess |
| Standard | 100 to 300 mcg | 30 to 60 min before bed | 5 to 10 days on, 5 to 14 days off |
| Higher (rarely needed) | 300 to 500 mcg | 30 to 60 min before bed | Watch for grogginess |
| Withdrawal protocol (medical supervision) | 200 to 500 mcg | Pre-bed, sometimes split AM and PM | 2 to 4 weeks continuous |
Why higher is not better
DSIP follows a U-shaped dose-response curve. At 50 to 300 mcg, sleep quality improves cleanly. Above 300 to 500 mcg, users report worsening morning grogginess, occasionally mild dizziness, and sometimes paradoxical sleep fragmentation (the dose disrupts sleep architecture instead of restoring it). The "more is better" instinct does not apply. If 200 mcg is not working after 7 nights, the issue is not the dose; it is something else (timing, lifestyle, underlying sleep pathology).
Reconstitution
For a 5 mg vial:
- Add 2 mL bacteriostatic water
- Final concentration: 2,500 mcg/mL
- On a U-100 insulin syringe: 4 units (0.04 mL) delivers 100 mcg, 8 units (0.08 mL) delivers 200 mcg
- Refrigerate after reconstitution. Use within 30 days.
For full reconstitution math, see our peptide reconstitution guide and the peptide calculator.
Cycling protocol
Most users follow 5 to 10 days on, then 5 to 14 days off. The reasoning is two-fold: DSIP appears to produce its strongest effect in the first 1 to 2 weeks of a cycle, and continuous use seems to produce diminishing returns rather than tolerance per se. Cycling resets the responsiveness. There is no documented physical dependence or withdrawal from stopping DSIP.
Nasal spray vs subcutaneous
Older studies used intravenous and intranasal routes. Modern community use is overwhelmingly subcutaneous because the lyophilized product is sold as injectable. Intranasal DSIP exists but bioavailability and dosing equivalence are poorly characterized. If you must use intranasal, double the dose as a rough equivalent and titrate.
DSIP Side Effects
The side-effect profile is one of the cleanest among sleep peptides.
| Side effect | Frequency | Onset | Management |
|---|---|---|---|
| Vivid dreams | 20 to 30% | First few nights | Often desirable; usually fades after first cycle |
| Morning grogginess | 5 to 15% (dose-dependent) | Morning after | Lower the dose; consider earlier bedtime |
| Mild dizziness | 3 to 8% | Hours after dose | Hydration; usually transient |
| Mild headache | 3 to 5% | First few uses | Resolves on its own; lower starting dose |
| Injection site reactions | Common but mild | Hours | Rotate sites |
| Mild nausea | 2 to 3% | Within hour of injection | Eat a small snack with the dose |
| Mood changes | 2 to 5% | Variable | Discontinue if persistent |
| Flushing | 1 to 3% | Within hour | Usually mild and self-limiting |
| Paradoxical fragmentation | 1 to 3% at high doses | Same night | Lower the dose |
What is not seen
- No documented lethal dose in animal studies
- No physical dependence after stopping
- No tolerance development requiring escalating doses
- No documented severe organ toxicity
- No documented hormonal disruption beyond GH-axis effects
Contraindications
- Pregnancy or breastfeeding (no human data; avoid)
- Severe untreated sleep apnea (DSIP increases deep sleep, which can extend apnea episodes)
- Active opioid or sedative dependence without medical supervision
- Severe psychiatric disorders without medical input
DSIP vs Melatonin, Selank, Oxytocin and Prescription Sleep Aids
Each tool fits a different problem.
| Compound | Best for | Mechanism | Honest limitation |
|---|---|---|---|
| DSIP | Sleep architecture quality, deep sleep, withdrawal | Delta-wave promotion, HPA modulation | Not a circadian shifter; does not "knock out" |
| Melatonin | Circadian timing, jet lag, shift work | Suprachiasmatic nucleus binding | Does not deepen sleep; doses over 1 mg often counterproductive |
| Selank | Anxiety-driven insomnia | GABAergic, anxiolytic | Best for anxiety; not architecture-changing for non-anxious users |
| Oxytocin | Stress-driven insomnia, social anxiety | Bonding hormone, indirect cortisol reduction | Effect on sleep is secondary; intranasal route is short-acting |
| Z-drugs (zolpidem) | Acute sleep onset issues | GABA-A potentiation | Disrupted architecture, dependence, complex sleep behaviors |
| Trazodone (off-label) | Maintenance insomnia, mood-related | Serotonin antagonism | Morning carryover, priapism risk |
Stacking DSIP
The most useful stacks:
- DSIP + low-dose melatonin (0.3 to 1 mg). Pairs circadian timing (melatonin) with architecture quality (DSIP). Common in shift workers and travelers.
- DSIP + magnesium glycinate (300 to 400 mg). Cheap, well-tolerated, complementary mechanism through NMDA modulation and muscle relaxation.
- DSIP + CJC-1295/ipamorelin. The GH stack uses DSIP to deepen the sleep window where most GH pulses naturally occur, amplifying the GH peptide's effect.
- DSIP + epitalon (10 mg per cycle). Both Khavinson-school and longevity-adjacent peptides; sometimes paired in anti-aging stacks.
Where to Buy DSIP
Sourcing matters more for DSIP than most people realize.
DSIP is sold by online peptide vendors as an unapproved compound. The FDA placed it on Category 2 ("do not compound") in September 2023, which means compounding pharmacies cannot prepare it for individual patients. The drug itself is not a controlled substance and not a banned substance, but the regulatory pathway through compounding is closed. Vendor quality varies. Verify:
- HPLC purity 98% or higher
- Mass spectrometry confirming the WAGGDASGE sequence (M+H around 849)
- Sterility testing for the lyophilized injectable
- Batch-specific COA rather than a generic certificate
For broader sourcing standards see our peptide vendor guide and how to read a peptide COA.
Frequently Asked Questions
Medical disclaimer. This article is informational only and does not replace individualized medical advice. DSIP is not approved by the FDA for any human use and was placed on Category 2 ("do not compound") in September 2023. Anyone considering use, especially in the context of pre-existing sleep disorders (apnea), psychiatric conditions, substance dependence, or pregnancy, should speak with a qualified clinician.